Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

The delay for Stealth Biotherapeutics comes amid a heightened focus on the impact FDA job cuts might have on drug reviews.

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...